Edition:
United States

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.25USD
21 Sep 2018
Change (% chg)

$-0.03 (-2.34%)
Prev Close
$1.28
Open
$1.28
Day's High
$1.28
Day's Low
$1.24
Volume
36,933
Avg. Vol
76,149
52-wk High
$2.50
52-wk Low
$1.05

Latest Key Developments (Source: Significant Developments)

Scynexis Q2 Loss Per Share $0.23
Thursday, 9 Aug 2018 04:15pm EDT 

SCYNEXIS Inc ::SCYNEXIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.  Full Article

Scynexis Reports Positive Results From Phase 2B Vulvovaginal Candidiasis Study
Tuesday, 10 Jul 2018 04:05pm EDT 

July 11 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS POSITIVE RESULTS FROM PHASE 2B DOSE-FINDING STUDY OF ORAL SCY-078 IN VULVOVAGINAL CANDIDIASIS.SCYNEXIS INC - CLINICALLY AND MYCOLOGICALLY EFFECTIVE AND WELL-TOLERATED ORAL DOSE OF SCY-078 IDENTIFIED FOR USE IN PHASE 3 REGISTRATION PROGRAM.SCYNEXIS INC - INITIATION OF PHASE 3 REGISTRATION PROGRAM IN VVC PLANNED FOR Q4 OF 2018.SCYNEXIS INC - BELIEVES THAT 600MG DOSE OF SCY-078 IS OPTIMAL DOSE REGIMEN FOR USE IN VVC PHASE 3 REGISTRATION PROGRAM.SCYNEXIS INC - SCY-078 ORAL DOSE REGIMEN OF 600MG COMPARED FAVORABLY TO FLUCONAZOLE REFERENCE ARM IN THIS PATIENT POPULATION.SCYNEXIS INC - ORAL SCY-078 600MG DOSE WAS GENERALLY WELL-TOLERATED.SCYNEXIS INC - ALL FIVE DOSES OF ORAL SCY-078 DEMONSTRATED MEANINGFUL CLINICAL AND MYCOLOGICAL ACTIVITY.  Full Article

Scynexis Q1 Loss Per Share $0.12
Tuesday, 8 May 2018 04:20pm EDT 

May 8 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q1 LOSS PER SHARE $0.12.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants
Tuesday, 6 Mar 2018 09:25am EST 

March 6 (Reuters) - Scynexis Inc ::SCYNEXIS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.SCYNEXIS INC - SHARES AND WARRANTS ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $1.69 PER SHARE.  Full Article

Scynexis Provides Corporate And SCY-078 Pipeline Update
Thursday, 4 Jan 2018 04:05pm EST 

Jan 4 (Reuters) - Scynexis Inc ::SCYNEXIS PROVIDES CORPORATE AND SCY-078 PIPELINE UPDATE.SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​.SCYNEXIS INC - ‍PLANS TO INITIATE A PHASE 2B STUDY OF SCY-078 IN INVASIVE CANDIDIASIS WITH LIPOSOMAL IV FORMULATION IN Q4 OF 2018​.SCYNEXIS - ‍ANTICIPATES DOSE REGIMEN SELECTED FROM DOVE STUDY TO BE SUBSEQUENTLY EVALUATED IN PHASE 3 STUDIES FOLLOWING END-OF-PHASE 2 MEETING WITH FDA​.  Full Article

Scynexis reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:20pm EST 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis CEO Marco Taglietti​ buys 10,000 shares of co's common stock on Aug 15
Thursday, 17 Aug 2017 09:36am EDT 

Aug 17 (Reuters) - Scynexis Inc :Scynexis Inc CEO‍ Marco Taglietti​ reports purchase of 10,000 shares of co's common stock on Aug 15 at $1.61 per share - SEC filing.  Full Article

Scynexis Q2 loss per share $0.16
Tuesday, 8 Aug 2017 04:25pm EDT 

Aug 8 (Reuters) - Scynexis Inc :Scynexis reports second quarter 2017 financial results and provides company update.Q2 loss per share $0.16.Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis Q1 loss per share $0.19
Monday, 8 May 2017 04:20pm EDT 

May 8 (Reuters) - Scynexis Inc ::Scynexis reports first quarter 2017 financial results and provides update on iv formulation development status.Q1 loss per share $0.19.Q1 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis delays initiation of new clinical studies
Thursday, 2 Mar 2017 04:05pm EST 

Scynexis Inc : Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request . Scynexis Inc says ongoing and future trials using oral formulation of SCY-078 are unaffected by this regulatory action . Scynexis -meeting with FDA to discuss these data and to agree on subsequent clinical studies with iv formulation of SCY-078 is scheduled for Q2 of 2017 .Scynexis -FDA has informed company to hold initiation of any new clinical studies with intravenous (IV) formulation of SCY-078 until FDA completes review.  Full Article

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE